Chao J, Chai K X, Chen L M, Xiong W, Chao S, Woodley-Miller C, Wang L X, Lu H S, Chao L
Department of Biochemistry, Medical University of South Carolina, Charleston 29425.
J Biol Chem. 1990 Sep 25;265(27):16394-401.
Kallikrein-binding protein was purified to apparent homogeneity from rat serum by Affi-Gel Blue, DEAE-Sepharose CL-6B, Sephacryl S-200 chromatography, and preparative gel electrophoresis or high performance liquid chromatography. The purified protein migrates as a single band of 60 kDa in a sodium dodecyl sulfate-polyacrylamide gel under reducing conditions. It is an acidic protein with isoelectric points ranging from 4.2 to 4.6. The amino terminus of the binding protein is an Asp residue as determined by sequence analysis. It forms a 92-kDa sodium dodecyl sulfatestable complex with kallikrein with a t1/2 of 18 min. Western blot and radioimmunoassay showed a distribution of the kallikrein-binding protein in serum, urine, and various tissues with a 5-10-fold lower amount in spontaneously hypertensive rats (SHR) than in Wistar-Kyoto rats (WKY). A full length cDNA clone encoding the kallikrein-binding protein was isolated from a rat liver cDNA library by immunoscreening and the translated amino acid sequence matches the amino-terminal 29-amino acid sequence of the binding protein. The cDNA sequence shares 68.8% identity with human alpha 1-antichymotrypsin and is identical to that of a rat hepatic protein. Dot blot analysis shows that kallikrein-binding protein is expressed at high levels in the liver and at low levels in the lung, salivary gland, and kidney. Its mRNA level in the liver decreases by 2-fold after acute phase inflammation and is higher in male than in female rats. Genomic Southern blot analyses reveal restriction fragment length polymorphisms between SHR and WKY rats in the binding protein locus. The results indicate that rat kallikrein-binding protein belongs to the serpin superfamily and its level is significantly reduced in the spontaneously hypertensive rats.
通过Affi-Gel Blue、DEAE-琼脂糖CL-6B、Sephacryl S-200层析以及制备性凝胶电泳或高效液相色谱法,从大鼠血清中纯化激肽释放酶结合蛋白至表观均一。在还原条件下,纯化后的蛋白在十二烷基硫酸钠-聚丙烯酰胺凝胶中迁移为一条60 kDa的单带。它是一种酸性蛋白,等电点范围为4.2至4.6。通过序列分析确定,结合蛋白的氨基末端为天冬氨酸残基。它与激肽释放酶形成一种92 kDa的十二烷基硫酸钠稳定复合物,半衰期为18分钟。蛋白质印迹法和放射免疫测定显示,激肽释放酶结合蛋白在血清、尿液和各种组织中均有分布,自发性高血压大鼠(SHR)体内的含量比Wistar-Kyoto大鼠(WKY)低5至10倍。通过免疫筛选从大鼠肝脏cDNA文库中分离出编码激肽释放酶结合蛋白的全长cDNA克隆,其翻译后的氨基酸序列与结合蛋白的氨基末端29个氨基酸序列相符。该cDNA序列与人类α1-抗糜蛋白酶的同源性为68.8%,与大鼠肝脏蛋白的序列相同。斑点印迹分析表明,激肽释放酶结合蛋白在肝脏中高表达,在肺、唾液腺和肾脏中低表达。急性期炎症后,其在肝脏中的mRNA水平下降2倍,雄性大鼠中的水平高于雌性大鼠。基因组Southern印迹分析揭示了SHR和WKY大鼠在结合蛋白基因座处的限制性片段长度多态性。结果表明,大鼠激肽释放酶结合蛋白属于丝氨酸蛋白酶抑制剂超家族,其水平在自发性高血压大鼠中显著降低。